These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 12496938

  • 1. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.
    Balla A, Sershen H, Serra M, Koneru R, Javitt DC.
    Neuropsychopharmacology; 2003 Jan; 28(1):34-44. PubMed ID: 12496938
    [Abstract] [Full Text] [Related]

  • 2. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
    Balla A, Koneru R, Smiley J, Sershen H, Javitt DC.
    Neuropsychopharmacology; 2001 Aug; 25(2):157-64. PubMed ID: 11425499
    [Abstract] [Full Text] [Related]

  • 3. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function.
    Sershen H, Balla A, Aspromonte JM, Xie S, Cooper TB, Javitt DC.
    Neurochem Int; 2008 Jan; 52(1-2):119-29. PubMed ID: 17716783
    [Abstract] [Full Text] [Related]

  • 4. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine.
    Takahata R, Moghaddam B.
    Neuropsychopharmacology; 2003 Jun; 28(6):1117-24. PubMed ID: 12700703
    [Abstract] [Full Text] [Related]

  • 5. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.
    Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H.
    Neuropsychopharmacology; 2004 Feb; 29(2):300-7. PubMed ID: 14560321
    [Abstract] [Full Text] [Related]

  • 6. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats.
    Shoblock JR, Sullivan EB, Maisonneuve IM, Glick SD.
    Psychopharmacology (Berl); 2003 Feb; 165(4):359-69. PubMed ID: 12491026
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion.
    Ventura R, Alcaro A, Cabib S, Conversi D, Mandolesi L, Puglisi-Allegra S.
    Neuropsychopharmacology; 2004 Jan; 29(1):72-80. PubMed ID: 12968132
    [Abstract] [Full Text] [Related]

  • 11. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat.
    Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH.
    Behav Brain Res; 1995 Dec 14; 72(1-2):103-14. PubMed ID: 8788863
    [Abstract] [Full Text] [Related]

  • 12. Repeated amphetamine administration alters the expression of mRNA for AMPA receptor subunits in rat nucleus accumbens and prefrontal cortex.
    Lu W, Chen H, Xue CJ, Wolf ME.
    Synapse; 1997 Jul 14; 26(3):269-80. PubMed ID: 9183816
    [Abstract] [Full Text] [Related]

  • 13. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys.
    Adams BW, Bradberry CW, Moghaddam B.
    Synapse; 2002 Jan 14; 43(1):12-8. PubMed ID: 11746729
    [Abstract] [Full Text] [Related]

  • 14. Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats.
    Kusljic S, van den Buuse M, Gogos A.
    J Integr Neurosci; 2022 Jan 28; 21(1):17. PubMed ID: 35164453
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat.
    Umino A, Takahashi K, Nishikawa T.
    Br J Pharmacol; 1998 May 28; 124(2):377-85. PubMed ID: 9641556
    [Abstract] [Full Text] [Related]

  • 16. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide.
    Javitt DC, Sershen H, Hashim A, Lajtha A.
    Neuropsychopharmacology; 1997 Sep 28; 17(3):202-4. PubMed ID: 9272487
    [Abstract] [Full Text] [Related]

  • 17. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
    Mouri A, Noda Y, Noda A, Nakamura T, Tokura T, Yura Y, Nitta A, Furukawa H, Nabeshima T.
    Mol Pharmacol; 2007 Jun 28; 71(6):1598-609. PubMed ID: 17344353
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: a model for schizophrenia.
    Jodo E.
    J Physiol Paris; 2013 Dec 28; 107(6):434-40. PubMed ID: 23792022
    [Abstract] [Full Text] [Related]

  • 20. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.
    Egerton A, Reid L, McGregor S, Cochran SM, Morris BJ, Pratt JA.
    Psychopharmacology (Berl); 2008 May 28; 198(1):37-49. PubMed ID: 18427784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.